Trial · NCT02708680
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 1b: Participants Experiencing DLT | Phase 1b Dose Determination: Entinostat Plus Atezolizumab | 0 | Participants | ||
| Phase 1b: Determination of the RP2D | Phase 1b Dose Determination: Entinostat Plus Atezolizumab | 5 | milligram | ||
| Phase 2 Expansion: Duration of Progression-free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | Phase 2 Expansion: Entinostat Plus Atezolizumab | 1.68 | 95% Confidence Interval 1.41 to 3.09 | months | |
| Phase 2 Expansion: Duration of Progression-free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | Phase 2 Expansion: Placebo Plus Atezolizumab | 1.51 | 95% Confidence Interval 1.41 to 2.43 | months | |
| Phase 2 Expansion: Duration of PFS Using Immune Response RECIST (irRECIST) | Phase 2 Expansion: Entinostat Plus Atezolizumab | 1.68 | 95% Confidence Interval 1.45 to 3.81 | months | |
| Phase 2 Expansion: Duration of PFS Using Immune Response RECIST (irRECIST) | Phase 2 Expansion: Placebo Plus Atezolizumab | 1.54 | 95% Confidence Interval 1.41 to 2.83 | months | |
| Phase 2 Expansion: Overall Response Rate (ORR) Using RECIST 1.1 and irRECIST | Phase 2 Expansion: Entinostat Plus Atezolizumab | ORR per RECIST 1.1 | 12.5 | percentage of participants | |
| Phase 2 Expansion: Overall Response Rate (ORR) Using RECIST 1.1 and irRECIST | Phase 2 Expansion: Placebo Plus Atezolizumab | ORR per RECIST 1.1 | 2.4 | percentage of participants | |
| Phase 2 Expansion: Overall Response Rate (ORR) Using RECIST 1.1 and irRECIST | Phase 2 Expansion: Entinostat Plus Atezolizumab | ORR per irRECIST 1.1 | 12.5 | percentage of participants | |
| Phase 2 Expansion: Overall Response Rate (ORR) Using RECIST 1.1 and irRECIST | Phase 2 Expansion: Placebo Plus Atezolizumab | ORR per irRECIST 1.1 | 2.4 | percentage of participants | |
| Phase 2 Expansion: Clinical Benefit Rate (CBR) Using RECIST 1.1 and irRECIST | Phase 2 Entinostat Plus Atezolizumab | CBR per RECIST 1.1 | 15.0 | percentage of participants | |
| Phase 2 Expansion: Clinical Benefit Rate (CBR) Using RECIST 1.1 and irRECIST | Placebo Plus Atezolizumab | CBR per RECIST 1.1 | 7.3 | percentage of participants | |
| Phase 2 Expansion: Clinical Benefit Rate (CBR) Using RECIST 1.1 and irRECIST | Phase 2 Entinostat Plus Atezolizumab | CBR per irRECIST 1.1 | 15.0 | percentage of participants | |
| Phase 2 Expansion: Clinical Benefit Rate (CBR) Using RECIST 1.1 and irRECIST | Placebo Plus Atezolizumab | CBR per irRECIST 1.1 | 7.3 | percentage of participants | |
| Phase 2 Expansion: Overall Survival (OS) | Phase 2 Expansion: Entinostat Plus Atezolizumab | 12.25 | 95% Confidence Interval 5.49 to 21.16 | months | |
| Phase 2 Expansion: Overall Survival (OS) | Phase 2 Expansion: Placebo Plus Atezolizumab | 11.20 | 95% Confidence Interval 7.43 to 15.77 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02708680/results